Roche Says MabThera Can Extend Leukaemia Patients’ Lives

ZURICH, Nov 21 (Reuters) - Roche Holding AG said on Friday its top-selling cancer drug MabThera helped patients with Chronic Lymphocytic Leukaemia (CLL) to live longer without their disease getting worse, according to a second late-stage study.